Free Trial

Aerovate Therapeutics (AVTE) News Today

Aerovate Therapeutics logo
$7.72 +0.30 (+3.98%)
As of 05/20/2025

AVTE Latest News

Aerovate Therapeutics, Inc. stock logo
Jefferies Financial Group Inc. Makes New $1.59 Million Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jefferies Financial Group Inc. bought a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 600,000 shares of the company's stock, valued
Aerovate Therapeutics, Inc. stock logo
60,000 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Acquired by Bridgeway Capital Management LLC
Bridgeway Capital Management LLC purchased a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 60,000 shares of the company's stock, valued at appro
Aerovate Therapeutics, Inc. stock logo
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Renaissance Technologies LLC lifted its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 149.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,600 shares of the company's stock after purchasing an additi
Aerovate Therapeutics, Inc. stock logo
Braidwell LP Buys Shares of 1,440,499 Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Braidwell LP purchased a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,440,499 shares of the company's stock,
Aerovate Therapeutics, Inc. stock logo
Blackstone Inc. Takes Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Blackstone Inc. acquired a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 499,566 shares of the company's stock, valued at
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics (AVTE) to Release Earnings on Monday
Aerovate Therapeutics (NASDAQ:AVTE) will be releasing its Q4 2024 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-aerovate-therapeutics-inc-stock/)
Aerovate Therapeutics, Inc. stock logo
JPMorgan Chase & Co. Has $178,000 Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
JPMorgan Chase & Co. grew its position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 1,021.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,165 shares of the company's stock after purchasing an additional 61,174 shares
Aerovate Therapeutics, Inc. stock logo
Allostery Investments LP Takes Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Allostery Investments LP purchased a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 850,684 shares of the company's stock, valued at approximately $2,254,0
Aerovate Therapeutics, Inc. stock logo
Investors Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE)
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 9,373 call options on the stock. This is an increase of approximately 2,291% compared to the average volume of 392 call options.
Aerovate Therapeutics, Inc. stock logo
Nantahala Capital Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Nantahala Capital Management LLC acquired a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 482,928 shares of the company's stock, valued at approximately $1,
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) to Issue Dividend of $2.40
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) declared a dividend on Wednesday, April 9th. Shareholders of record on Friday, April 25th will be given a dividend of 2.40 per share on Monday, April 28th. The ex-dividend date is Tuesday, April 29th.
Aerovate Therapeutics, Inc. stock logo
Affinity Asset Advisors LLC Purchases 200,000 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Affinity Asset Advisors LLC raised its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 800,000 shares of the company's stock afte
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Shares Bought by ADAR1 Capital Management LLC
ADAR1 Capital Management LLC lifted its holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 720.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 928,016 shares of the company's stock after purchas
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics (NASDAQ:AVTE) Issues Quarterly Earnings Results, Meets Expectations
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19).
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics (AVTE) Expected to Announce Quarterly Earnings on Monday
Aerovate Therapeutics (NASDAQ:AVTE) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports.
Aerovate Therapeutics, Inc. stock logo
Analysts Offer Predictions for AVTE FY2029 Earnings
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Aerovate Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico forecasts that the company will post
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 4,020,000 shares, a growth of 6.9% from the January 15th total of 3,760,000 shares. Based on an average daily trading volume, of 221,800 shares, the short-interest ratio is presently 18.1 days. Approximately 20.5% of the company's shares are short sold.
Aerovate Therapeutics, Inc. stock logo
Deltec Asset Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Deltec Asset Management LLC bought a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 194,124 shares of the company's stock, valued
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 35.5% in January
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 31st total of 1,860,000 shares. Based on an average trading volume of 768,100 shares, the short-interest ratio is currently 3.3 days. Approximately 12.9% of the shares of the stock are sold short.
Aerovate Therapeutics, Inc. stock logo
Jane Street Group LLC Trims Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jane Street Group LLC trimmed its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 86.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,805 shares of the company's stock after selli
Unusually active option classes on open January 16th
Aerovate Therapeutics, Inc. stock logo
Stock Traders Buy High Volume of Aerovate Therapeutics Call Options (NASDAQ:AVTE)
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Traders bought 3,010 call options on the company. This is an increase of approximately 338% compared to the typical volume of 687 call options.
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Rises By 35.5%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 15th total of 1,860,000 shares. Approximately 12.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 768,100 shares, the days-to-cover ratio is presently 3.3 days.
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Decreases By 5.3%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,790,000 shares, a decrease of 5.3% from the November 15th total of 1,890,000 shares. Currently, 9.1% of the shares of the stock are sold short. Based on an average trading volume of 765,600 shares, the short-interest ratio is currently 2.3 days.
Aerovate Therapeutics, Inc. stock logo
GSA Capital Partners LLP Purchases 287,163 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
GSA Capital Partners LLP raised its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 226.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 413,795 shares of the
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 17.3%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 549,800 shares, a decrease of 17.3% from the October 15th total of 665,000 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average daily volume of 750,300 shares, the short-interest ratio is currently 0.7 days.
Aerovate Therapeutics, Inc. stock logo
Wedbush Forecasts Higher Earnings for Aerovate Therapeutics
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Analysts at Wedbush boosted their FY2024 EPS estimates for Aerovate Therapeutics in a research note issued to investors on Wednesday, November 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($2.85) per share for
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift
Aerovate Therapeutics, Jade Biosciences enter merger agreement
Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

AVTE Media Mentions By Week

AVTE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AVTE
News Sentiment

1.79

0.65

Average
Medical
News Sentiment

AVTE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AVTE Articles
This Week

2

1

AVTE Articles
Average Week

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AVTE) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners